Impact of peptide receptor radionuclide therapy (PRRT) on the quality of life in patients with neuroendocrine tumours.

“Impact of peptide receptor radionuclide therapy (PRRT) on the quality of life in patients with neuroendocrine tumours. Fernando H(1), Vito I(1), Santillan N(1), Gnanasegaran G(1), Quigley AM(1), Grossman A(2), Hayes AR(2), Mandair D(2), Toumpanakis C(2), Caplin M(2), Navalkissoor S(1). Author information: (1)Department of Nuclear Medicine, Royal Free London NHS Foundation Trust, London, UK. (2)Department of NET Unit, ENETS Centre of Excellence, Royal Free London NHS Foundation Trust, London, UK. As peptide receptor radionuclide therapy (PRRT) maintains a key role in the treatment of neuroendocrine tumours (NETs), there is growing recognition of the importance of evaluating patient-reported health related quality of life (HRQoL). To assess this impact meaningfully, validated instruments such as the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaires are invaluable. This study aims to evaluate the impact of PRRT on the HRQoL of patients with NETs, using generic cancer and GI-NET-specific EORTC questionnaires to provide a comprehensive understanding of how PRRT influences patient wellbeing beyond traditional clinical endpoints. Between 2015 and 2025, patients who underwent PRRT at Royal Free London Hospital, and consented to this study, completed GI.NET21 and C30 questionnaires before PRRT is administered at each cycle. Patients who completed the pre-therapy questionnaire and at least one post-PRRT questionnaire were included in this study. The response format of both questionnaires is a 4-point Likert scale. Responses to the questionnaire were linearly transformed to a 0-100 scale using EORTC guidelines. A mean score difference >5 between any treatment cycles was considered clinically relevant, and p <.05 was considered statistically significant. GI.NET HRQoL questionnaire was completed by 267 patients, and C30 questionnaires by 147 patients. There was a statistically significant improvement between the pre-therapy score and all post PRRT treatment cycle scores in symptom scales, disease-related worries, and social function with GI.NET 21. This improvement was visible even after one PRRT cycle. A non-statistically significant improvement in overall score was seen in the pre therapy score and the third post therapy score in the C30 questionnaire. PRRT improves the quality of life and disease-specific concerns of NETs using a NET-specific HRQoL assessment tool. © 2026 British Society for Neuroendocrinology.”